1. de Miguel M, Calvo E. Clinical Challenges of Immune Checkpoint Inhibitors. Vol. 38, Cancer Cell. Cell Press; 2020. p. 326–33.
2. Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Vol. 62, International Immunopharmacology. Elsevier B.V.; 2018. p. 29–39.
3. Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Vol. 21, Molecular Cancer. BioMed Central Ltd; 2022.
4. Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Vol. 50, Experimental and Molecular Medicine. Nature Publishing Group; 2018.
5. Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations. Vol. 6, Journal for ImmunoTherapy of Cancer. BioMed Central Ltd.; 2018.